No abstract

Introduction: Psychiatric emergencies constitute between 1% - 10% of general emergencies in Spain, of which a quarter will end up being hospital admissions. There is little literature on patients who are referred from general to specialized hospitals. Methods: Cross-Sectional study of all the patients referred in 2018. Sociodemographic variables and clinical variables, such as diagnosis and discharge destination, were analyzed. An analysis was performed by comparing means with the Chi Square test. Results: 433 derived emergencies were analyzed. Most of the patients were women. The main reason for derivation were suicide attempts. Of those patients, 40% required hospitalizations. More than 50% of the derived emergencies were referred to the home and followed up on an outpatient basis. Conclusion: Most derived emergencies are referred to the home after evaluation. This implies that most are not life-threatening and that with adequate tools for evaluating suicide risk, we could avoid transfers and improve the resolution of these cases.

age 59 years (range 41-83); 62.5% men). The median number of bags per patient was 13.5 (range 3-66). Conclusion and relevance The CPRP in the pharmacy service increases the safety of administration, allows preparation under aseptic conditions and enables the optimisation of available stock. As it contains more volume, it facilitates the work and protects the nursing staff by reducing the frequency of contact with the patient.

Background Alzheimer's disease (AD) is the main cause of dementia in developed countries. Sleep disturbances have been shown to increase the risk of AD, however, benzodiazepine (BZD) consumption has also been shown to increase this risk in some cohort studies. Purpose The objective of the study was to assess the risk of AD incidence in a cohort of patients exposed to BZD. Material and methods Community-based retrospective cohort study from 1 January 2002 to 31 December 2015. Consumption was expressed in defined daily doses (DDD) accumulated by individuals. Three DDD intervals were established (1-90, 90-180 and >180). All approved BZD were included in the Medicines Catalogue of the Spanish Medicines Agency, as well as the BZD analogues (zoplicona, zolpidem). The patients treated with BZD during the 5 years immediately prior to diagnosis were excluded. The relationship between the BZD consumption categories and the development of AD was analysed by the Chi 2 test and adjusted logistic regression models. Cox proportional hazards models were also used to consider the time to AD development.Results The cohort included 84 543 individuals consuming BZD and similar, with an average age in 2002 of 65 years. During follow-up, 584 new cases of AD were diagnosed. In the Cox models adjusted for year of birth, sex and comorbidities, taking as a reference the first category of BZD consumption (1-90 DDD), there was a 12-fold increase in the risk of developing AD in participants with cumulative consumption from 90 to 180 DDD (Hazard ratio (95% CI): 11.6 (3.8-35.7), P-value<0.001) and 78 times higher in participants with more than 180 accumulated DDD (Hazard ratio (95% CI): 78.0 (29.1-208.8), P-value<0.001). The study according to type of BZD revealed slightly higher incidences of AD in the participants in the highest category of consumption (>180 DDD) of BZD of intermediate-long action 1.20% with respect to those of short-intermediate action 1.11%. Conclusion The long-term use of BZD increases the risk of developing AD. The establishment of new treatments with BZD should be restricted to the most serious cases and programmes of deprescription should be developed.

No abstract